1. Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer
- Author
-
Abbas Walji, Sonia DelRizzo, Elisabetta Bianchi, Jonathan D. Mortison, Vladimir Simov, Yingzi Yue, Thomas J. Tucker, Peter Goldenblatt, Alexander Stoeck, Raffaele Ingenito, Edward DiNunzio, Christopher Sondey, Hui Wan, Erin F. DiMauro, Venkat Sriraman, Victor Serebrov, My Sam Mansueto, Scott A. Johnson, Todd Mayhood, Guo Feng, and Michael D. Altman
- Subjects
MafG Transcription Factor ,NF-E2-Related Factor 2 ,Peptide ,Electrophoretic Mobility Shift Assay ,Pembrolizumab ,chemistry.chemical_compound ,Structure-Activity Relationship ,Drug Stability ,Transcription (biology) ,Neoplasms ,Drug Discovery ,medicine ,Humans ,Homology modeling ,Ternary complex ,Transcription factor ,Pharmacology ,chemistry.chemical_classification ,Chemistry ,Organic Chemistry ,Cancer ,General Medicine ,DNA ,respiratory system ,medicine.disease ,Antioxidant Response Elements ,Drug Design ,Cancer research ,Peptides ,Half-Life ,HeLa Cells - Abstract
Pathway activating mutations of the transcription factor NRF2 and its negative regulator KEAP1 are strongly correlative with poor clinical outcome with pemetrexed/carbo(cis)platin/pembrolizumab (PCP) chemo-immunotherapy in lung cancer. Despite the strong genetic support and therapeutic potential for a NRF2 transcriptional inhibitor, currently there are no known direct inhibitors of the NRF2 protein or its complexes with MAF and/or DNA. Herein we describe the design of a novel and high-confidence homology model to guide a medicinal chemistry effort that resulted in the discovery of a series of peptides that demonstrate high affinity, selective binding to the Antioxidant Response Element (ARE) DNA and thereby displace NRF2-MAFG from its promoter, which is an inhibitory mechanism that to our knowledge has not been previously described. In addition to their activity in electrophoretic mobility shift (EMSA) and TR-FRET-based assays, we show significant dose-dependent ternary complex disruption of NRF2-MAFG binding to DNA by SPR, as well as cellular target engagement by thermal destabilization of HiBiT-tagged NRF2 in the NCI–H1944 NSCLC cell line upon digitonin permeabilization, and SAR studies leading to improved cellular stability. We report the characterization and unique profile of lead peptide 18, which we believe to be a useful in vitro tool to probe NRF2 biology in cancer cell lines and models, while also serving as an excellent starting point for additional in vivo optimization toward inhibition of NRF2-driven transcription to address a significant unmet medical need in non-small cell lung cancer (NSCLC).
- Published
- 2021